The Internet Journal of Otorhinolaryngology™ ISSN: 1528-8420

| Home | Editors | Current Issue | Archives | Instructions for Authors | Disclaimer | Bookmark and Share Share with others |
 

Aetiological causes of reversible sensorineural hearing loss

Aftab Ahmed FRCS (ORL-HNS)
Specialist Registrar
Department of Otolaryngology
Doncaster Royal Infirmary Physical Address

Shahed Quraishi FRCS (ORL-HNS)
Consultant
Department of Otolaryngology
Doncaster Royal Infirmary Physical Address

Citation: A. Ahmed & S. Quraishi : Aetiological causes of reversible sensorineural hearing loss . The Internet Journal of Otorhinolaryngology. 2007 Volume 6 Number 2

Keywords: sensorineural hearing loss | reversible | aetiology

 

Abstract

The vast majority of sensorineural hearing loss cases are irreversible. However there is a significant proportion of cases in which the hearing loss recovers. A knowledge of the aetiological causes of reversible sensorineural deafness cases can allow early diagnosis and correct treatment to be implemented. The purpose of this article is to review the documented literature on the aetiological causes of reversible sensorineural hearing loss.


Introduction

Reversible sensorineural hearing loss occurs in a significant proportion of cases. Although the precise pathophysiology in many of these causative factors remains unclear it is nevertheless important to be aware of numerous aetiologies to enable a prompt diagnosis and correct treatment to be implemented. This article reviews the documented aetiological causes of sensorineural hearing loss.

Aetiologies

(i) Ototoxicity

There are numerous drugs which are known to cause damage to the inner ear which can result in reversible or irreversible hearing loss, tinnitus and dysequilibrium. Drugs which have been associated with reversible sensorineural hearing loss (SNHL) include:

a) Salicylate-induced ototoxicity was first reported in 1877 by Muller.1 Aspirin is probably the most common cause of drug- induced ototoxicity although the majority of it is reversible.2 Tinnitus tends to precede the deafness which is bilateral and affects all the frequencies. Both the tinnitus and SNHL develop within a few days of treatment and tend to reverse within a few days of withdrawing aspirin.2,3,4,5 Although the required dose of aspirin to produce these symptoms is variable, most individuals exhibit some degree of symptoms at serum levels of 35mg/dl.2,5

The exact mechanism of action by the salicylates is not clearly understood. A change in the membrane permeability of the outer hair cells appears to play a significant role.2,3,4,5 A change in the cochlear blood supply as a result of the salicylate-induced imbalance of vasodilatory prostaglandins and vasoconstricting leukotrienes may also have an integral role.2,3,4

b) Quinine like aspirin can cause reversible SNHL associated with tinnitus and can occur in both healthy and malaria patients.2,6,7 The effects are rapid and resolve completely following withdrawal of the drug. It appears to alter the membrane function of the outer hair cells especially in the region of the lateral cisternae.2

Five months of treatment of rheumatoid arthritis with hydroxychloroquine which resulted in reversible SNHL has been reported in a patient.8 The mechanism of this ototoxicity is not known.

c) In 1965 Maher and Schreiner 9 first described the reversible SNHL and vertigo following intravenous administration of the loop diuretic ethacrynic acid. Loop diuretics e.g ethacrynic acid and frusemide may cause SNHL when administered parenterally in high doses, or if given rapidly even in low doses.10,11 Patients with existing hearing deficits, severe hypoalbinaemia, heart failure or severe renal failure are particularly susceptible to the ototoxic effects of these drugs.10,11 Experimental studies suggest that loop diuretics damage the stria vascularis and/or the outer hair cells of the cochlea 10It has been demonstrated that loop diuretics inhibit Na-K ATPase and adenyl cyclase in the stria.12Concurrent administration of loop diuretics with aminoglycosides can exacerbate or cause aminoglycoside ototoxicity.13

d) The macrolide antibiotic erythromycin is associated on rare occasions with SNHL which is reversible on discontinuation of the antibiotic.14,15,16,17,18,19 This bilateral and reversible loss is most likely to occur at doses of at least 4g/day.14,15,18Patients at increased risk of developing erythromycin-induced deafness include the elderly 15, patients with pre-existing hepatic or renal failure 15, and patients undergoing liver 19or renal transplantation.14

The precise mechanism of the loss of hearing is not known but it is thought that erythromycin exerts its effects on the central auditory pathway level, as there are associated reported features such as hallucinations and diplopia.14,15

e) Reversible bilateral SNHL has been reported following the administration of oral metronidazole.20Withdrawal of the antibiotic and oral steroid therapy resulted in return of normal hearing thresholds. The exact mechanism of action is unknown.

f) The chemotherapeutic agent cisplatin is known to cause permanent or transient SNHL.11,21,22,23,24 The deafness can also be associated with tinnitus 21Clinical studies have shown that this type of hearing loss is directly related to the total dose of cisplatin administered and to the peak serum concentrations.11

The precise mechanism of action is unknown but there is associated hair cell damage, inhibition of Na+-K(ATPase) in the outer hair cells of the cochlea 23and atrophy of the stria vascularis.2

g) With the increasing use of interferon, several new adverse effects including audiovestibular symptoms have been recognised. Sudden SNHL associated frequently with tinnitus has been reported to have developed several days after the commencement of interferon (both alpha and beta interferon).25,26,27 Complete resolution of the hearing loss in all the cases occurred within a month after discontinuation of interferon. The exact mechanism of action is unknown.

h) OKT3 (muromonab-CD3) is a murine monoclonal antibody used as an immunosuppressant following cadaveric renal transplants. Sudden SNHL (high frequency) within 48-72 hours of commencing OKT3 has been reported followed by complete resolution within 2 weeks after discontinuation of the drug.28,29 Transient tinnitus was also a frequent associated symptom. The mechanism of how OKT3 produces ototoxicity remains unclear.

i) Carbamazepine has been shown to be capable of delaying conduction of the auditory system both centrally and peripherally.30 Temporary bilateral SNHL has been reported following an overdose of carbamazepine (36g) in a patient.31 Two weeks later there was complete resolution of the deafness and the associated tinnitus and dizziness.

j) Treatment of partial seizures with sodium valproate has resulted in SNHL which resolved following discontinuation of the drug.32 The mechanism of this rare adverse effect of sodium valproate is unclear.

k) The anti-epileptic drug vigabatrin has recently been reported to cause reversible SNHL.33 Discontinuation of the drug led to complete recovery of the hearing loss. Vigabatrin is a GABA-based drug and animal studies have shown that GABA is an important inhibitory neurotransmitter for cochlear inner and outer hair cells.33

l) Chronic use of amphetamines has been reported to cause SNHL which has reversed within 4 to 10 days of cessation of amphetamine use.34 Prolonged and heavy use of amphetamines can lead to neuronal damage and neurotransmitter depletion but the precise mechanism of the ototoxic effect is unknown.

m) Animal model studies have demonstrated SNHL induced by lithium 35 and also interleukin-2 36 which has reversed following discontinuation of the drugs.

n) Chronic carbon monoxide (CO) exposure usually results in permanent, symmetrical and high frequency hearing loss and was first documented in 1948.37 Reversible SNHL following chronic CO exposure has been reported with improvement occurring over a period ranging from several weeks to 21 months. 37,38,39

Acute CO exposure is less common and typically produces a U shaped audiogram which is usually bilateral and may be asymmetrical with recovery usually taking several months.39,40,41,42

Carbon monoxide poisoning is often associated with headaches, nausea, lethargy, pulmonary oedema and arrythmias.38The symptoms are presumed to be due to tissue hypoxia due to the formation of carboxyhaemoglobin. Animal model studies suggest that free radicals may have an integral role 43and there may be an excitotoxic component as MK-801 which blocks the glutamate NMDA receptor has been shown to protect against CO ototoxicity.44

ii) Anaesthesia

a) General anaesthesia

Sudden reversible and irreversible SNHL has been reported following general anaesthesia involving both otolaryngological and non-otolaryngological procedures. The reversible hearing loss is unilateral or bilateral and the degree of recovery is variable.45,46,47,48,49,50

It is thought that the anaesthetic agent has a causative role in the deafness. The most common anaesthetic agent in these cases is nitrous oxide. Two theories have been suggested-‘implosive' and ‘explosive' routes. In the first route, rapid penetration of the highly soluble nitrous oxide results in an acute increase in middle ear pressure and subsequent rupture of the round window membrane.51 In the second, the nitrous oxide-induced increases in the venous and CSF pressure are transmitted to the perilymphatic space via the cochlear duct causing displacement or rupture of the membrane.52 The other anaesthetic agents e.g isoflurane and fentanyl may act indirectly on the auditory pathway by altering the general haemodynamics e.g hypotension.53

b) Spinal anaesthesia and lumbar puncture

The first reported case of hearing impairment after spinal anaesthesia was reported in 1914.54 Since then, it has been well documented that reversible SNHL can occur after spinal anaesthesia and following procedures involving lumbar puncture.55,56,57,58,59,60,61 The hearing loss is either unilateral or bilateral, low frequency and usually reverses spontaneously although there are a few documented cases where the SNHL has not reversed.58

The precise mechanism of this transient hearing loss has not yet been completely established. It has been suggested that following dural puncture the decrease in the CSF volume and pressure that occurs leads to a decrease of perilymph as there is a direct communication between the CSF and perilymph via the cochlear aqueduct. The reduction in perilymphatic pressure would then induce a transient endolymphatic expansion for equilibration.55,62,63 This endolymphatic hydrops is associated with the hearing loss and restoration of the CSF and inner ear volumes would then lead to a return of normal hearing thresholds.

The contrast medium, metrizamide which is used in lumbar myelography is associated with transient deafness. The mechanism of action is probably due to a hydrostatic imbalance between the perilymph and CSF resulting from a decreased CSF osmolality.61

iii) Infective

a) Bacterial

Bacterial meningitis can leave up to 10% of patients particularly children with permanent SNHL.64, 65 Transient SNHL has also been reported following bacterial meningitis.66,67,68,69,70 Both types of hearing loss tend to develop in the early part of the illness.66,68In the majority of the reports the deafness tends to reverse after weeks or months 68,69,70 but in a large multicentre trial involving children the improvement in most of the affected cases occurred within 48 hours.66

The cochlea appears to be auditory lesion site due to the loss of otoacoustic emissions.66Animal studies also support the integral role played by the cochlea.71,72 The mechanism is unclear but it may result from the effect of bacterial toxins or inflammatory mediators on the hair cells of the organ of Corti.71,73

Syphilis (congenital or acquired) can produce otological manifestations including SNHL, tinnitus and imbalance.74,75,76,77,78,79 The SNHL may be sudden, fluctuant, progressive, unilateral or bilateral. Treponema pallidum has an ability to persist in several sites including the temporal bone.77Treatment with antibiotics and steroids shows a variation in response.79

Lyme disease is caused by infection with the spirochaete Borrelia burgdorferi and like syphilis may result in neurological manifestations e.g facial nerve palsy and SNHL. The SNHL which is sudden in onset, can affect low or high frequencies and may respond to treatment with antibiotics. Both partial 80 and complete recovery 81 (usually after a few months) of the hearing loss following treatment has been reported. Indeed a case has been reported in which the hearing loss completely reversed more than two years following treatment.82 SNHL has been reported to occur in 15% of cases of late Lyme disease without recovery of hearing.83 The precise pathogenesis of hearing loss in Lyme disease is presently not known.82

Animal studies involving instillation of pseudomonas aeruginosa exotoxin A and pneumococcal toxins into middle ear have demonstrated the onset of SNHL which has reversed in a few weeks.84,85

b) Fungal

Reports in the literature have shown an association between hearing loss and cryptococcal meningitis.86,87 A case of a patient with cryptococcal meningoencephalitis in whom the SNHL hearing loss reversed following antifungal treatment has been reported.87

c) Mycoplasmas

Infection with Mycoplasma pneumoniae has been reported in a case which resulted in unilateral SNHL (associated with tinnitus and vertigo) which reversed completely following treatment with doxycycline.88

Mycoplasma, bacteria and viruses have all been implicated in the aetiology of bullous myringitis. Prospective studies of bullous myringitis by Hoffman 89and Hariri 90 have demonstrated a significant incidence of SNHL (65% and 66% respectively) with complete resolution of the hearing loss in 57% and 60% in the 2 series respectively. The mechanism of the hearing loss remains unclear.

d) Viral

Infection with varicella zoster virus typically results in SNHL and facial palsy. There is great variation in the degree of hearing loss and the amount of recovery of the loss. Acute SNHL which is usually unilateral is a well reported reversible complication of mumps.91

The exact mechanism has not yet been definitively proven but host immune mediated response in the cochlea appears significant.92

iv) Autoimmune

Autoimmune SNHL was first described as a clinical entity in 1979 by McCabe.93 Clinical presentation and prompt diagnostic confirmation can lead to successful management of the deafness by medical therapy. However recognition of the disease is not straight forward in particular due to lack of simple and reliable diagnostic tests and the paucity of temporal bone tissue from untreated patients.94,95

The precise mechanisms involved in the hearing loss are unclear. Animal model studies have led to several immunological mechanisms being postulated. These include humoral mechanisms involving specific autoantigens in the inner ear (Type II); circulating immune complexes involving bacterial and viral antibodies (Type III); cell mediated immunity involving cytotoxic T cells (Type IV); and autoantibodies directed against type II collagen.94 There are no randomised trials of therapy for autoimmune SNHL and the treatment approach is based upon anecdotal experience, case series and inference from treatment of related conditions. Steroid and cyclophosphamide immunosuppression has been the main form of treatment.93,95

Reversible SNHL has been reported in the following specific autoimmune disorders:

a) Cogan's syndrome

This syndrome is characterised by ocular inflammation classically interstitial keratitis and audio-vestibular symptoms including SNHL, vertigo and tinnitus.95Hearing fluctuation coincides with exacerbations and remissions of the disease. Temporal bone histopathological findings include endolymphatic hydrops, lymphocyte infiltration and organ of Corti degeneration.96,97 Steroid and cyclophosphamide therapy are the mainstay of treatment.

b) Wegener's granulomatosis

The 3 main components of this disease are focal necrotising glomerulonephritis, necrotising granulomatous lesions in the upper and/or lower respiratory tracts and systemic vasculitis. In contrast to Cogan's syndrome the most common otologic deficit is conductive loss (otitis media with effusion).94,95 However SNHL usually in combination with conductive deafness has been reported.98,99,100,101 The SNHL has improved following treatment with steroids and cyclophosphamide.99,101

c) Polyarteritis nodosa

This vasculitic disease affects small and medium-sized arteries. Although uncommon SNHL which is sudden and bilateral has been reported.102,103,104 Temporal bone histopathological findings include arteritis of the internal auditory artery.105 Treatment with steroids and cyclophosphamide 102,103 or azathioprine 104 has resulted in improvement of the hearing loss.

d) Kawasaki disease

Kawasaki disease is an acute self-limited vasculitis that affects primarily medium sized arteries of infants and children. Prospective studies have demonstrated transient SNHL over a period ranging from 1 week to 4 months.106,107 The mechanism of the hearing loss remains unclear.

v) Metabolic

Haemodialysis

SNHL is frequently reported in patients with chronic renal failure.108 The aetiology of this hearing impairment remains unclear, however factors such as uraemic toxins, electrolyte imbalance and hypotension have been suggested to play a role.109 However opinion remains divided on the effect haemodialysis has on the hearing impairment. Studies involving long term haemodialysed patients who had been receiving dialysis ranging from 5 years 110 to 10 years 109have shown no significant alteration in the hearing. These are supported by studies assessing hearing after a single haemodialysis session and hearing assessed by distortion product otoacoustic emissions both in children and adults.111,112 In contrast other studies have reported that following a single session of haemodialysis, the hearing impairment has either deteriorated 113,114 or improved.115,116,117

vi) Haematolgical

Hyperviscosity syndrome

The features of hyperviscosity syndrome include headache, visual disturbances, vertigo, tinnitus and SNHL. These clinical features are due to the elevated blood viscosity and resulting slowly circulating oxygen-deficient blood. It is postulated that the elevated viscosity causes partial occlusion of the cochlear vessels resulting in ischaemia of the cochlea and subsequent hearing loss.118

Haematological disorders that have exhibited reversible SNHL which is attributable to hyperviscosity syndrome include:

Leukaemia: recent studies have implicated both acute and chronic leukaemia in the development of sudden SNHL which can be the presenting clinical feature.118,119,120. Temporal bone histopathological studies of affected patients include leukocyte infiltration and inner ear haemorrhage.119,120 Lowering of the leukocyte count by leukapheresis or steroid and chemotherapy treatment can lead to reversal of the hearing loss.118,119,120

Essential thrombocytosis: a case of sudden SNHL in a patient with thrombocytosis which reversed following plateletpheresis is reported in the literature.121

Waldenstrom's macroglobulinaemia is an uncommon disorder in which there is excess production of monoclonal macroglobulin IgM. A case has been reported in a patient with Waldenstrom's macroglobulinaemia in whom the SNHL improved along with the other hyperviscosity-related symptoms following treatment with fludarabine.122

vii) Neoplasms

a) Vestibular schwannomas

Hearing loss associated with vestibular schwannomas (VS) has been reported to resolve spontaneously or to improve following corticosteroid treatment.123,124

Reports of hearing improvement after surgical removal of VS in particular small tumours exist but not extensively.125,126,127,128,129,130 Although the exact mechanism for the deafness is unclear, one theory that has been put forward is that it is due to a vascular compression phenomenon which is relieved following removal of the tumour129,130 and the reduction of tumour mass in the case of corticosteroids.129Others postulate a mechanical conduction block of the cochlear nerve action potential theory.131

b) Cerebello-pontine angle tumours

Recovery of severe SNHL following total surgical removal of cerebellopontine angle tumours –meningioma and jugular foramen neurinoma has been reported.132It is thought relief of tumour compression maintaining the arachnoidal sheaths of the cochlear nerve would make the recovery of its function possible.132

c) Carotid body tumour

Removal of a carotid body tumour in a patient with dysphagia, tinnitus and ipsilateral SNHL led to recovery of the hearing loss.133

viii) Vestibular

Meniere's disease

Meniere's disease is characterised by recurrent attacks of deafness, tinnitus and vertigo. The SNHL improves between attacks even to normal levels. The pattern of hearing loss is typically low frequency but eventually affects all frequencies and is progressive.134

Distension of the endolymphatic space is the main feature and another frequent histopathological finding is membraneous labyrinth rupture. The exact mechanism involved remains unclear. One theory involves rupture of the membranes leading to mixing of the endolymph and perilymph leading to electrochemical imbalance.135 Another theory postulates alteration in the blood supply leading to alteration in the constituents of the endolymph.134

Symptomatic relief of symptoms which is primarily aimed at vertigo includes dietary advice, medical e.g vestibular sedatives, and surgical interventions e.g saccus decompression.134

ix) Neurological

a) Multiple sclerosis

Sudden SNHL is a rare manifestation of multiple sclerosis (MS) and it tends to occur within the first years of the disease although later onset is also described.136It is due to the demyelination of the auditory pathway and usually occurs when other areas of the brainstem are affected. Recovery of the hearing loss has been reported in the literature.136,137,138

b) Sarcoidosis

This multisystem granulomatous disease can involve the VIIIth cranial nerve leading to SNHL and vertigo. It is presumed that the symptoms are due to direct infiltration or compression of the cranial nerve.139 Reversal of the SNHL has been reported following steroid treatment but this is very rare.140

x) Traumatic

a) Blast injury

SNHL following blast injuries is most severe immediately after the explosion and usually recovers within 24 hours.141 This temporary threshold shift is often accompanied by vertigo and tinnitus which are also usually transient. The mechanism of the hearing loss involves damage to the outer hair cells.

b) Perilymph fistula

Leakage of perilymph into the middle ear following rupture of inner ear membranes can occur following head injury, diving barotraumas and stapedial surgery. Dizziness may be accompanied by tinnitus and SNHL which may fluctuate.134Spontaneous resolution may occur following a period of bed rest with elevation of the head. Surgical attempt at closure of the leak may result in improvement of the dizziness and prevent further deterioration in the deafness.134

xi) Miscellaneous

a) Hypotension

A retrospective study demonstrated that a group of patients with sudden SNHL which improved had lower mean arterial pressures and in whom the deafness recovered more easily following treatment.142 This has led to the suggestion that at least in some cases cochlear damage may be caused by a perfusion deficit as a result of the combined effect hypotension and impaired vasomotor regulation.142

b) Biotinidase deficiency

A case of a child with total biotinidase deficiency who developed bilateral SNHL is reported.143 Treatment with biotin led to improvement of the hearing thresholds.

c) Menstrual cycle

Bilateral transient SNHL associated with the onset of menstruation has been reported in a patient.144 Treatment with diuretics perimenstrually led to improvement in the transient loss. The precise mechanism of action in this case remains unclear.

d) Psychogenic

A case of a patient with acute SNHL who demonstrated further deterioration in the hearing levels following a panic anxiety attack has been reported.145 Treatment with corticosteroids and psychiatric counselling resulted in a return to normal thresholds except in the high-frequency range immediately after the treatment.

e) Intra-operative deafness during posterior fossa surgery

Two patients undergoing microvascular decompression for trigeminal neuralgia developed intra-operative hearing loss diagnosed by complete loss of brainstem evoked potentials during the surgery. The resulting prominent vascular compression around the cochlear nerve in both patients was immediately decompressed resulting in restoration of the hearing loss.146

Conclusions

It must be emphasised that the above is not a complete list of all the aetiological causes of reversible SNHL but it is nevertheless hopefully a comprehensive report of the documented causes.

An accurate history taking with a background knowledge of the possible causes of SNHL can lead to appropriate investigations being undertaken. Although the vast majority of SNHL cases are irreversible, there are however as highlighted above certain aetiologies which can be reversed if recognised early and appropriate management implemented. A prompt and correct diagnosis and treatment may prevent further deterioration of the hearing loss and even result in recovery.

Correspondence

Mr Aftab Ahmed
Department of ENT
Doncaster Royal Infrmary
Armthorpe Road
Doncaster.
South Yorkshire DN2 5LT
England.
Email: [ahmed.aftab@virgin.net]

References

1. MULLER G. (1877) Beitrag zur wirking der salicylasuren natrons beim dibetes melleus. Berlin klinik Wochenshrift. 14, 29-31 (s)

2. WRIGHT T. (1998) Ototoxicity. In:Diseases of the Ear Ludman H. & Wright T. (Eds) London, Arnold.p 503-515 (s)

3. JUNG T., RHEE C., LEE C. et al. (1993) Ototoxicity of salicylate, non-steroidal anti-inflammatory drugs and quinine. Otolaryngol Clin North Am. 26, 791-810 (s)

4. CAZALS Y. (2000) Auditory sensori-neural alterations induced by salicylate. Prog Neurobiol. 62, 583-631 (s)

5. MYERS E., BERNSTEIN J. & FOSTIROPOLOUS G. (1965) Salicylate ototoxicity: A clinical study. N Engl J Med. 273, 587-590 (s)

6. TANGE R.A., DRESCHLER W.A., CLAESSEN F.A. et al. (1997) Ototoxic reactions of quinine in healthy persons and patients with Plasmodium falciparum infection. Auris Nasus Larynx24 (2), 131-136 (s)

7. ROCHE R.J., SILAMUT K., PUKRITTAYAKAMEE S. et al. (1990) Quinine induces reversible high tone hearing loss. Br J Clin Pharmacol. 29 (6), 780-782 (s)

8. SECKIN U., OZORAN K., IKINCIOGULLARI A. et al. (2000) Hydroxychloroquine ototoxicity in a patient with rheumatoid arthritis. Rheumotol Int. 19(5) 203-204 (s)

9. MAHER J.F. & SCHREINER G.E. (1965) Studies on ethacyrnic acid in patients with refractory oedema. Ann Intern Med. 62, 15-19 (s)

10. RYBAK L. (1993) Ototoxicity of loop diuretics. Otolaryngol Clin North Am. 26, 829-844 (s)

11. SELIGMANN H., PODOSHIN L., BEN-DAVID J. et al. (1996) Drug-induced tinnitus and other hearing disorders. Drug Saf. 14, 198-212 (s)

12. THALMANN R., ISE I., BOHNE B.A. et al. (1977) Actions of loop diuretics and mercurials upon the cochlea. Acta Otolaryngologica83, 221-232 (s)

13. LERNER S. & MATZ G. (1980) Aminoglycoside ototoxicity. Am J Otolaryngol. 1, 169-179 (s)

14. VASQUEZ E.M., MADDUX S.M., SANCHEZ J. et al. (1993) clinically Significant hearing loss in renal allograft recipients treated with intravenous erythromycin. Arch Intern Med. 153, 879-882 (s)

15. SACRISTAN J.A., SOTO J. & de COS M.A. (1993) Erythromycin-induced hypoacusis: 11 new cases and literature review. Ann Pharmacother. 27, 950-955 (s)

16. MINTZ U., AMIR J. & de VRIES A. (1973) Transient perceptive deafness due to erythromycin lactobionate. JAMA225, 1122-1123 (s)

17. KARMODY C.S. & WEINSTEIN L. (1977) Sensorineural hearing loss with intravenous erythromycin lactobionate. Ann Otol. 86, 9-11 (s)

18. BRUMMET R. & FOX K. (1989) Vancomycin and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother. 33, 791-796 (s)

19. MORAL A., NAVASA M., RIMOLA A. et al. (1994) Erythromycin ototoxicity in liver transplant patients. Transplant7, 62-64 (s)

20. IQBAL S.M., MURTHY J.G., BANNERJEE P.K. et al. (1999) Metronidazole ototoxicity - report of two cases. J Laryngo Otol.113, 355-357 (s)

21. HAYES D.M., CVITKOVIC E. & GOLBEY R.B. (1977) High dose cisplatinum diammine dichloride. Cancer39, 1372-1381 (s)

22. MONTAGUTI M., BRANDOLINI C., FERRI G.G. et al. (2002) Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention. Acta Otorhinolatyngol Ital. 22(1), 14-18 (s)

23. REED E. (1993) Anticancer drugs: Platinum analogs. In:Cancer Principles and Practice of Oncology. Devita V, Hellman S, Rosenberg S (Eds) Philadelphia, J.B. Lippincott. 390-397 (s)

24. RIGGS L., BRUMMETT R., GUITJENS S.et al. (1996) Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope106, 401-406 (s)

25. KANDA Y., SHIGENO K., KINOSHITA N. et al. (1994) Sudden hearing loss associated with interferon. Lancet343, 1134-1135 (s)

26. KANDA Y., SHIGENO K., MATSUO H. et al. (1995) Interferon-induced sudden hearing loss. Audiology34(2), 98-102 (s)

27. GORUR K., KANDEMIR O., UNAL M. et al. (2003) The effect of recombinant interferon alpha treatment on hearing thresholds in patients with chronic viral hepatitis B. Auris Nasus Larynx30, 41-44 (s)

28. HARTNICK C.J, COHEN A.F. & SMITH R.V. (1997) Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3). Ann Otol Rhinol Laryngol. 106(8), 640-642 (s)

29. HARTNICK C.J., SNITH R.V., TELLIS V. et al. (2000) Reversible sensorineural hearing loss following administration of muromonab-CD3 (OKT3) for cadaveric renal transplant immunosuppression. Ann Otol Rhinol Laryngol. 109, 45-47 (s)

30. JAPARIDZE G., KVEMADZE D., GELADZE T. et al (1993) Effects of carbamazepine on auditory brainstem response and slow cortical potential in epileptic patients. Epilepsia34, 1105-1109 (s)

31. de la CRUZ M. & BANCE M. (1999) Carbamazepine-induced sensorineural hearing loss. Arch Otolaryngol Head Neck Surg. 125, 225-227 (s)

32. ARMON C., BROWN E., CARWILE S. et al. (1990) Sensorineural hearing loss: a reversible effect of valproic acid. Neurology40, 1896-1898 (s)

33. PAPADEAS E., POLYCHRONOPOULOS P., PAPATHANASOPOULOS P. et al. (2003) Sensorineural hearing loss: a reversible effect of vigabatrin. Neurology61(7), 1021-1022 (s)

34. IQBAL N. (2002) Hearing loss in amphetamine users. J Psychoactive Drugs34(4), 401-407 (s)

35. HORNER K.C., HUANG Z.W., HIGUERIE D. et al. (1997) Reversible hearing impairment induced by lithium in the guinea pig. Neuroreport14;8(6), 1341-1345 (s)

36. KUBO T., ANNIKO M., STENQVIST M. et al. (1998) Interleukin-2 affects cochlear function gradually but reversibly. ORL J Otorhinolaryngol Relat Spec. 60(5), 272-277 (s)

37. LUMIO J. (1948) Clinical findings following chronic carbon monoxide exposure. Acta Otolaryngol 1-112 (s)

38. LEE C., ROBINSON P. & CHELLADURAI J. (2002) Reversible sensorineural hearing loss. Int J Pediatr Otorhinolaryngol. 66(3), 297-301 (s)

39. HASSAN M.S., RAY J. & WILSON F. (2003) Carbon monoxide poisoning and sensorineural hearing loss. J Laryngol Otol. 117, 134-137 (s)

40. MORRIS T.M. (1969) Deafness following acute carbon monoxide poisoning. J Laryngol Otol. 83, 1219-1225 (s)

41. BAKER S. & LILLEY D. (1977) Hearing loss from acute carbon monoxide intoxication. Ann Otol Rhinol Laryngol. 86, 323-328 (s)

42. MAKASHIMA K. (1988) Otoneurologic manifestations following carbon monoxide poisoning. J Acoust Soc Am. 84, 38 (s)

43. FLETCHER L., LIU T. & PEARCE T. (1997) Cochlear protection from carbon monoxide exposure by free radical blockers in the guinea pig. Toxicol Appl Pharmacol. 142, 47-55 (s)

44. LIU Y. & FLETCHER L. (1995) MK-801 protects against carbon monoxide induced hearing loss. Toxicol Appl Pharmacol. 132, 196-202 (s)

45. PAU H., SELVADURAI. & MURTY G.E. (2000) Reversible sensorineural hearing loss after non-otological surgery under general anaesthesia. Postgrad Med J. 76 (895), 304-306 (s)

46. PATTERSON M.E. & BARLETT P.C. (1979) Hearing impairment caused by intratympanic pressure changes during general anaesthesia. Laryngoscope86, 399-404 (s)

47. MILLEN S.J., TOOHILL R.J. & LEHMEN R.H. (1982) Sudden sensorineural hearing loss: operative complication in non-otological surgery. Laryngoscope92, 613-617 (s)

48. SEGAL S., MAN A. & WINERMAN I. (1984) Labyrinthine membrane rupture caused by elevated intratympanic pressure during general anaesthesia. Am J Otol. 5, 308-310 (s)

49. HOCHERMANN M. & REIMER A. (1989) Hearing loss after general anaesthesia. A case report and review of literature. J Laryngol Otol. 101, 1079-1082 (s)

50. BELAN A., RIDA A., HAMOUD N. et al. (1994) bilateral sensorineural hearing loss after general anaesthesia. Ann Fr Anesth Reanim. 13, 400-402 (s)

51. GOODHILL V. (1971) Sudden deafness and round window rupture. Laryngoscope81, 1462-1474 (s)

52. GOODHILL V., HARRIS I., BROCKMAN S.J. et al. (1973) Sudden deafness and labyrinthine window rupture. Ann Otol Rhinol Laryngol. 82, 2-12 (s)

53. KAUFMAN L. & TABERNER P.V. (1996) Pharmacology in the practice of anaesthesia. London, Arnold, 71, 420-422 (s)

54. TERRIEN F. & PRELAT P. (1914) Paresis of the sixth cranial nerve and bilateral hearing decrease following spinal anaesthesia. Arch d'opthalmol. 34, 111-116 (s)

55. WALSTED A. (2000) Effects of cerebrospinal fluid loss on hearing. Acta Otolaryngol. 543, 95-98 (s)

56. LEE C. (1990) Hearing loss after spinal anaesthesia. Anesth Analg. 71, 561-569 (s)

57. FOG J., WANG L., SUNBERG A. et al. (1990) Hearing loss after spinal anaesthesia is related to needle size. Anesth Analg. 70, 517-522 (s)

58. MICHEL O. & BRUSIS T. (1992) Hearing loss as a sequel of lumbar puncture. Ann Otol Rhinol Laryngol.101, 390-394 (s)

59. PANNING B., MEHLER D. & LEHNHARDT E. (1983) Transient low frequency hypoacusis after spinal anaesthesia. Lancet2, 582 (s)

60. WANG L.P., FOG J. & BOVE M. (1987) Transient hearing loss following spinal anaesthesia. Anaesthesia42, 1258-1263 (s)

61. HUSSAIN S.S.M., HEARD C.M.B. & BEMBRIDGE J.L. (1996) Hearing loss following spinal anaesthesia with bupivicaine. Clin Otolaryngol. 21, 449-454 (s)

62. WALSTED A. (1998) Effects of cerebrospinal fluid loss on the auditory system. Clinical and experimental investigations. Dan Med Bull. 45/3, 268-281 (s)

63. MARCHBANKS R.J. & REID A. (1990) Cochlear and cerebrospinal fluid pressure: their inter-relationship and control mechanisms. Br J Audiol. 24, 179-187 (s)

64. BARAFF L.J., LEE S.J. &SCHRINGER D.L. (1993) Outcomes of bacterial meningitis in children: a meta-analysis. Paediatr Infect Dis J. 12, 389-394 (s)

65. FORTNUM H.M. (1992) Hearing impairment after bacterial meningitis. Arch Dis Chil. 67, 1228-1233 (s)

66. RICHARDSON M.A., REID A., TARLOW M.J. et al. (1997) Hearing loss during bacterial meningitis. Arch Dis Child. 76, 134-138 (s)

67. GUISCAFRE H., BENITEZ-DIAZ L., MARTINEZ M.C. et al. (1984) Reversible hearing loss after meningitis: prospective assessment using auditory evoked responses. Ann Otol Rhinol Laryngol. 93, 229-232 (s)

68. KAPLAN S.L., CATLIN F.I., WEAVER T. et al. (1984) Onset of hearing loss in children with bacterial meningitis. Paediatrics73, 575-578 (s)

69. NADOL J.B. (1978) Hearing loss as a sequela of meningitis. Laryngoscope88, 739-755 (s)

70. OZDAMAR O., KRAUS N. & STEIN L. (1983) Auditory brainstem responses in infants recovering from bacterial meningitis. Arch Otolaryngol. 109, 13-18 (s)

71. TARLOW M.J., COMIS S.D. & OSBORNE M.P. (1991) Endotoxin induced damage to the cochlea in guinea pigs. Arch Dis Child. 66, 181-184 (s)

72. BHATT S.M., LAURETANO A., CABELLOS C. et al. (1993) Progression of hearing loss in experimental pneumococcal meningitis: correlation with cerebrospinal fluid cytochemistry. J Infect Dis. 167, 675-683 (s)

73. HUANG M.H., DULON D. & SCHACHT J.S. (1990) Outer hair cells as potential targets of inflammatory mediators. Ann Otol Rhinol Laryngol. 99, 35-38 (s)

74. KARMODY C.S. & SCHUKNECHT H.F. (1966) Deafness in congenital syphilis. Arch Otolaryngol. 83, 18-27 (s)

75. BECKER G.D. (1979) Late syphilitic hearing loss: A diagnostic and therapeutic dilemma. Laryngoscope89, 1273-1288 (s)

76. McNULTY J.S. & FASSETT R.L. (1981) Syphilis; An otolaryngologic perspective. Laryngoscope91, 889-905 (s)

77. BOOTH J.B. (1982) Medical management of sensorineural hearing loss. J Laryngol Otol.96, 673-684 (s)

78. ADAMS D.A., KERR A.G., SMYTH G.D.L. et al. (1983) Congenital syphilitic deafness - a further review. J Laryngol Otol. 97, 399-404 (s)

79. STECKELBERG J.M., ROCHESTER M.N & McDONALD T.J. (1984) Otologic involvement in late syphilis. Laryngoscope94, 753-757 (s)

80. HANNER P., ROSENHALL U., EDSTROM S. et al. (1989) Hearing impairment in patients with antibody production against Borrelia burgdoferi antigen. Lancet13-15 (s)

81. MOSCATELLO A.L., WORDEN D.L., NADELMAN R.B. et al. (1991) Otolaryngologic aspects of Lyme disease. Laryngoscope101, 592-595 (s)

82. QUINN S.J., BOUCHER B.J. & BOOTH J.B. (1997) Reversible sensorineural hearing loss in Lyme disease. J Laryngol Otol. 111, 562-564 (s)

83. LOGIGIAN E.L., KAPLAN R.F. & STEERE A.C. (1990) Chronic neurologic manifestations of Lyme disease. N Engl J Med. 323, 1438-1444 (s)

84. STENQVIST M., ANNIKO M. & PETTERSSON A. (1997) Effect of pseudomonas aeruginosa exotoxin A on inner ear function. Acta Otolaryngol. 117, 73-79 (s)

85. KUBO T., ANNIKO M., HSU W.J. et al. (1998) Pneumococcal toxins reversibly affect cochlear eletrophysiology. Oto Rhino Laryngologia-Nova. 8(2), 59-65 (s)

86. TJOIE L.T., YEW K.Y. & CHAI B.T. (1985) Cryptococcal meningitis. J Neurol Neurosurg Psychyiatry48, 853-858 (s)

87. MAYER J.M., CHEVALIER X., ALBERT E. et al. (1990) Reversible hearing loss in a patient with cryptococcosis. Arch Otolaryngol Head Neck Surg. 116, 962-964 (s)

88. SHANON E., REDIANU C., ZIKK D. (1982) Sudden deafness due to infection by Mycoplasma pneumoniae. Ann Otol Rhinol Laryngol. 91, 163-165 (s)

89. HOFFMEN R.A. & SHEPSMAN D.A (1983) Bullous myringitis and sudden hearing loss. Laryngoscope93, 1544-1545 (s)

90. HARIRI M.A. (1990) Sensorineural hearing loss in bullous myringitis. A prospective study of eighteen patients. Clin Otolaryngol. 15, 351-353 (s)

91. HYDEN D. (1996) Mumps labyrinthitis, endolymphatic hydrops and sudden deafness in succession in the same ear. ORL J Otorhinolaryngol Relat Spec. 58(6), 338-342 (s)

92. HARRIS J.P.& SHARP P. (1990) Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss. Laryngoscope100, 516-524 (s)

93. McCABE B.F. (1979) Autoimmune sensorineural hearing loss. Ann Otol. 88, 585-589 (s)

94. MATHEWS J. & KUMAR B.N. (2003) Autoimmune sensorineural hearing loss. Clin Otolaryngol. 28, 479-488 (s)

95. STONE J.H. & FRANCIS H.W. (2000) Immune-mediated inner ear disease. Curr Opin Rheumatol. 12, 32-40 (s)

96. WOLFF D., BERNHARD W.G., TSUTSUMI S. et al. (1965) The pathology of Cogan's Syndrome causing profound deafness. Ann Otol Rhinol Laryngol. 74, 507-520 (s)

97. SCHUKNECHT H. & NADOL J. (1994) Temporal bone pathology in a case of Cogan's syndrome. Laryngoscope104, 1135-1142 (s)

98. ILLUM P.& THORBING K. (1982) Otological manifestations of Wegener's granulomatosis. Laryngoscope92, 801-804 (s)

99. McCAFFREY T.V., McDONALD T.J. et al. (1980) Otologic manifestations of Wegener's granulomatosis. Otolaryngol Head NeckSurg. 88 (5), (s)

100. KEMPF H.G. (1989) Ear involvement in Wegener's granulomatosis. Clin Otolaryngol. 14, 451-456 (s)

101. CLEMENTS P.R., MISTRY C.D. et al. (1989) Recovery from sensorineural deafness in Wegener's granulamotosis. J Laryngol Otol. 103, 1234 (s)

102. TSUNODA K., AKAOGI J., OHYA N. et al. (2001) Sensorineural hearing loss as the initial manifestation of polyarteritis nodosa. J Laryngol Otol. 115(4), 311-312 (s)

103. WOLF M., KRONENBERG J. et al. (1987) Rapidly progressive hearing loss as a symptom of polyarteritis nodosa. Am J Otolaryngol. 8(2), 105-108 (s)

104. ROWE-JONES J.M., MACALLAN D.C. & SOROOSHIAN M. (1990) Polyarteritis nodosa presenting as bilateral onset cochleo-vestibular failure in a young woman. J Laryngol Otol. 104, 562-564 (s)

105. GUSSEN P. (1977) Polyarteritis nodosa and deafness: a human temporal bone study. Arch Otorhinolaryngol. 217, 263-271 (s)

106. SUNDEL R.P., NEWBURGER J.W., McCILL T. et al. (1990) Sensorineural hearing loss associated with Kawasaki disease. J Paediatrics117, 371-377 (s)

107. KNOTT P.D., ORLOFF L.A., HARRIS J.P. et al. (2001) Sensorineural hearing loss and Kawasaki disease: a prospective study. Am J Otolaryngol. 22(5), 343-348 (s)

108. BERGSTROM L., JENKINS P., SANDO I. et al. (1973) Hearing loss in renal disease: clinical and pathological studies. Ann Otol. 82, 555-576 (s)

109. BAZZI C., VENTURINI C.T., PAGANI C. et al. (1995) Hearing loss in short and long-term haemodialysed patients. Nephrol Dial Transplant. 10, 1865-1868 (s)

110. MIRAHMADI M.K. & VAZIRI N.D. (1980) Hearing loss in end-stage renal disease - effects of dialysis. J Dial. 4, 159-16 (s)

111. STAVROULAKI P., NIKOLOPOULOS T.P., PSAROMMATIS I. et al. (2001) Hearing evaluation with distortion-product otoacoustic emissions in young patients undergoing haemodialysis. Clin Otolaryngol. 26, 235-242 (s)

112. OZTURAN O. & LAM S. (1998) The effect of haemodialysis on hearing using pure tone audiometry and distortion-product otoacoustic emissions. ORL. 60, 306-313 (s)

113. RIZVI S.S. & HOLMES R.A. (1980) Hearing loss from haemodialysis. Arch Otolaryngol. 106, 751-754 (s)

114. YASSIN A., SAFWAT F. & FATT-HI A. (1966) Ear, nose and throat manifestations in cases of renal failure treated by dialysis. Ann Rhinol Laryngol. 75, 192-201 (s)

115. GATLAND D., TUCKER B., CHALSTREY S. et al. (1991) Hearing loss in chronic renal failure: hearing threshold changes following haemodialysis. J R Soc Med.84, 587-589 (s)

116. KOMSUOGLU S., MEHTA R., JONES L.A. et al. (1985) Brainstem auditory evoked potentials in chronic renal failure and maintenance haemodialysis. Neurology35, 419-423 (s)

117. MAGLIULO G. GAGLIARDI M. & RALLI G. (1987) BSER audiometry in haemodialysis patients. Clin Otolaryngol. 12, 249-254 (s)

118. CHAE S.W., CHO J.H., LEE J.H. et al. (2002) Sudden hearing loss in chronic myelogenous leukaemia implicating the hyperviscosity syndrome. J Laryngol Otol. 116, 291-293 (s)

119. VELING M.C., WINDMILL I. & BUMPOUS J.M. (1999) Sudden hearing loss as a presenting manifestation of leukaemia. Otolaryngol Head Neck Surg. 120, 954-956 (s)

120. BAER M.R., STEIN R.S. & DESSYPRIS E.N. (1985) Chronic lymphocytic leukaemia with hyperleukocytosis: the hyperviscosity syndrome. Cancer56, 2865-2869 (s)

121. GRISELL D.L. & MILLS G.M. (1986) Reversible acute sensorineural hearing loss associated with essential thrombocytosis. Arch Intern Med. 146, 1813 (s)

122. SYMS M.J., ARCILA M.E. & HOLTEL M.R. (2001) Waldenstrom's macroglobulinaemia and sensorineural hearing loss. Am J Otolaryngol. 22(5), 349-353 (s)

123. BERENHOLZ L.P., ERIKSEN C. & HIRSCH F.A. (1992) Recovery from repeated sudden hearing loss with corticosteroid use in the presence of an acoustic neuroma. Ann Otol Rhinol Laryngol. 101, 827-831 (s)

124. BERG H.M., COHEN N.L., HAMMERSCHLAG P.E. et al (1986) Acoustic neuroma presenting as sudden hearing loss with recovery. Otolaryngol Head Neck Surg. 94, 15-22 (s)

125. COHEN N.L., RANSOHOFF J. & JACOBS J. (1985) Restoration of speech discrimination following subocciptal, transmeatal excision of extracanalicular acoustic neuroma. Otolaryngol Head Neck surg. 93, 126-131 (s)

126. FISCHER G., CONSTANTINI J.L. & MERCIER P. (1980) Improvement of hearing after microsurgical removal of acoustic neurinoma. Neurosurgery7, 154-159 (s)

127. SHELTON C. & HOUSE W.F. (1990) hearing improvement after acoustic tomour removal. Otolaryngol Head Neck Surg. 103, 963-965 (s)

128. TELIAN S.A., KEMINK J.L. & KILENY P.R. (1988) Hearing recovery following suboccipital excision of acoustic neuroma. Arch Otolaryngol Head Neck Surg114, 85-87 (s)

129. YANAGIHARA N. & ASAI M. (1993) Sudden hearing loss induced by acoustic neuroma: significance of small tumours. Laryngoscope103, 308-311 (s)

130. MEITELES L.Z., LIU J.K. & COULDWELL W.T. (2002) Hearing restoration after resection of an intracanalicular vestibular schwannoma: a role for emergency surgery? J Neurosurg. 96, 796-800 (s)

131. SAUNDERS J.E., LUXFORD W.M. ,DEVGAN K.K. et al. (1995) Sudden hearing loss in acoustic neuroma patients. Otolaryngol Head Neck Surg.113, 23-31 (s)

132. VELLUTINI E.A.S., CRUZ O.L.M., VELASCO O.P. et al. (1991) Reversible hearing loss from cerebellopontine angle tumours. Neurosurgery28(2), 310-312 (s)

133. TEMMEL A.F., KIERNER A.C., MUHM M. et al. (1999) Reversible sensorineural hearing impairment induced by a carotid body tumour. Eur Arch Otorhinolaryngol. 256(9), 466-469 (s)

134. LUDMAN H. (1998) Vestibular disorders. In: Diseases of the Ear. Ludman H & Wright T. (Eds) London, Arnold. 516-534 (s)

135. BROWN D.H. McCLURE J. & DOWNAR-ZAPOLSKI Z. (1988) The membrane rupture theory of Meniere's disease - is it valid? Laryngoscope98, 599-601 (s)

136. MARANGOS N. (1996) Hearing loss in multiple sclerosis: localisation of the auditory pathway lesion according to electrocochleographic findings. J Laryngol Otol. 110, 252-257 (s)

137. DRULOVIC B., RIBARIC-JANKES K., KOSTIC V.S. et al. (1994) Multiple sclerosis as the cause of sudden pontine deafness. Audiology33, 195-201 (s)

138. TABIRA T., TSUJI S., NAGASHIMA T. et al. (1981) Cortical deafness in multiple sclerosis. J Neurol Neurosurg Psych. 44, 433-436 (s)

139. JONES N. & LUDMAN H. (1998) Acquired sensorineural hearing loss. In: Diseases of the Ear. Ludman H & Wright T. (Eds) London, Arnold 495-502 (s)

140. JAHRSDOERFER R.A., THOMPSON E.G., JOHNS M.E. et al. (1981) Sarcoidosis and fluctuating hearing loss. Ann Otol Rhinol Laryngol. 90, 161-163 (s)

141. KERR A.G. & BYRNE J.E.T. (1975) Concussive effects of a bomb blast on the ear. J Laryngol Otol. 89, 131-143 (s)

142. PIRODDA A., SAGGESE D., FERRI G.G. et al. (1997) The role of hypotension in the pathogenesis of sudden hearing loss. Audiology36, 98-108 (s)

143. STRAUSSBERG R., SAIAG E., HAREL L. et al. (2000) Reversible deafness caused by bitidinase deficiency. Paediatr Neurol. 23(3), 269-270 (s)

144. SOUAID JP. & RAPPAPORT J.M. (2000) Fluctuating hearing loss associated with the menstrual cycle. J Otolaryngol. 30(4), 246-250 (s)

145. MORI S., FUJIEDA S., YAMAMOTO T. et al. (2002) Psychogenic hearing loss with panic anxiety attack after the onset of acute inner ear disorder. J Otorhinolarygol Relat Spec. 64(1), 41-44 (s)

146. WAHLIG J.B., KAUFMANN A.M., BALZER J. et al. (1999) Intra-operative loss of auditory function relieved by microvascular decompression of the cochlear nerve. Can J Neurol Sci. 26(1), 44-47 (s)

This article was last modified on Fri, 13 Feb 09 13:54:23 -0600

This page was generated on Sun, 21 Mar 10 14:45:18 -0500, and may be cached.
Advertisement